Volition's Nu.Q® Vet Cancer Test Now Available for Pre-Order at The Point-of-Care Through Heska Corporation

$HSKA
$VNRX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Get the next $HSKA alert in real time by email

HENDERSON, Nev., Feb. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces its Nu.Q® Vet Cancer Test is now available for pre-order to veterinarians at the point-of-care through Heska Corporation (NASDAQ:HSKA) ("Heska"). The Nu.Q® test will be showcased this weekend in Las Vegas at the 2023 Western Veterinary Conference, one of the world's largest veterinary conferences.

Heska's Nu.Q® Canine Cancer Screen and Monitor Test will operate on Heska's proprietary Element i+® Immunodiagnostic Analyzer, a point-of-care platform which provides veterinarians with rapid, accurate, low cost, and easy-to-use on-site testing in the veterinary clinic, to support clinical decision-making and improve patient outcomes.

Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: "This is a breakthrough moment for Volition: it is the first time the Nu.Q® platform is available outside of centralised laboratory testing. Our mission at Volition is to ensure that our Nucleosomics™ technology is accessible and affordable worldwide, to detect and monitor disease earlier and improve outcomes. We are delighted to be working with Heska and their remarkable point-of-care technology to enable vets, pets, and pet families to benefit from our innovative technology. We are thrilled to advance towards full commercial launch and license payment milestones."

Kevin Wilson, Heska's Chief Executive Officer and President said, "We are pleased now to offer our transformative Nu.Q® Canine Cancer Screen and Monitor Test at the point-of-care, which we believe will revolutionize canine cancer patient management. Available now for pre-order, the screen and monitoring test will assist veterinarians to detect cancer early, in the clinic, in minutes, and for under $50, to support clinical decision-making during annual check-ups, regular wellness exams, healthcare interventions, treatment cycles, and remission. While we also offer this technology at the central reference lab, we believe the benefits of point-of-care cancer screening and monitoring are significant and will provide outsized benefits to veterinarians, nursing and technical teams, pets, and pet families."

"With this forthcoming launch, millions of pets will have access to critical cancer screening and monitoring in the clinic, to catch, treat and drive recovery from cancers earlier, for better healthcare outcomes and peace of mind. We believe that this innovation will be transformative to veterinarian healthcare as Heska begins to roll it out exclusively to the point-of-care, with our global commercial launch targeted for early in the second quarter of this year," concluded Mr. Wilson.

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition's Nu.Q® technology go to: www.volition.com

Note to editors:

  1. Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test March 29 2022
  2. Findings from a clinical study conducted by Volition and Professor Wilson-Robles and the team at Texas A&M University, peer-reviewed and published in August 2022, showed that:

About Heska

Heska Corporation (NASDAQ:HSKA) sells, manufactures, markets, and supports diagnostic and specialty products and solutions for veterinary practitioners. Heska's portfolio includes point-of-care diagnostic laboratory instruments and consumables including rapid assay diagnostic products; digital cytology services; point-of-care digital imaging diagnostic products; local and cloud-based data services; practice information management software ("PIMS") and related software and support; reference laboratory testing; allergy testing and immunotherapy; heartworm preventive products; and vaccines. Heska's primary focus is supporting companion animal veterinarians in providing care to their patients. Heska's business is composed of two operating and reportable segments: North America and International. North America consists of the United States, Canada and Mexico. International consists of geographies outside of North America, primarily in Germany, Italy, Spain, France, Switzerland, Australia and Malaysia. Heska's strategic focus on point-of-care diagnostic laboratory and imaging products is included in both segments. The North America segment also includes the contract manufacturing of vaccines and pharmaceutical products and a small veterinary laboratory, and the international segment includes PIMS business and veterinary laboratories. For more information, please visit www.heska.com.

About Volition

Volition is a multi-national epigenetics company powered by Nu.Q®, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.

The contents found at Volition's and Heska's website addresses are not incorporated by reference into this document and should not be considered part of this document.  Such website addresses are included in this document as inactive textual references only.

Media Enquiries:

Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620

Jon Aagaard, Heska,  investorrelations@heska.com +1 970-617-8399

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's estimated market opportunity,  expectations related to the potential benefits under the License and Supply Agreement with Heska, including the timing and success of product launches, the effectiveness of Volition's blood-based diagnostic, prognostic and disease monitoring tests, and Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. 

Video - https://www.youtube.com/watch?v=sVc6kMCWkho

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/volitions-nuq-vet-cancer-test-now-available-for-pre-order-at-the-point-of-care-through-heska-corporation-301748809.html

SOURCE VolitionRx Limited

Get the next $HSKA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HSKA
$VNRX

CompanyDatePrice TargetRatingAnalyst
2/1/2023Buy → Hold
The Benchmark Company
1/6/2023$58.00Equal-Weight → Underweight
Morgan Stanley
3/1/2022$190.00 → $161.00Equal-Weight
Morgan Stanley
2/23/2022$300.00 → $250.00Overweight
JP Morgan
2/17/2022$8.00 → $7.00Overweight
Cantor Fitzgerald
1/6/2022$210.00Overweight
Piper Sandler
11/18/2021$190.00Equal-Weight
Morgan Stanley
11/16/2021$10.00 → $9.00Buy
Aegis Capital
More analyst ratings

$HSKA
$VNRX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis

    Expanding commercial offering as a bio-partnering model, currently in active discussions with pharmaceutical companies  HENDERSON, Nev., Feb. 6, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) Volition a multi-national epigenetics company, announces its first commercial sale of Volition's High Throughput Synthetic Sepsis method that measures Neutrophil Extracellular Traps "NETs" activation and inhibition in whole blood in real time, helping companies develop new therapeutics to combat sepsis and other NETs-related disease. Dr. Jasmine Kway, CEO of Singapore Volition and Commercial Lead for Nu.Q® Discover said: "Our High Throughput NETs model represents a critical breakthrough in unders

    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025

    HENDERSON, Nev., Feb. 5, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announced it will host a virtual investor event on Friday, February 14, 2025 at 8:00 AM ET, featuring Volition company management Dr. Andrew Retter, Chief Medical Officer and Gael Forterre, Chief Commercial Officer. To register, click here. Dr. Retter will focus on Nu.Q® NETs H3.1, a promising novel biomarker for early mortality and organ dysfunction in sepsis, and an independent predictor of the need for renal replacement therapy (RRT). Recently published results from a large-scale study indicate a potential clinical utility for risk stratification and earl

    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis

    HENDERSON, Nev., Jan. 30, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q®NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and septic shock patients. Findings published in the paper currently undergoing peer review and accessible on MEDRXIV, demonstrate Nu.Q® NETs H3.1 is a promising novel biomarker for early mortality and organ dysfunction in sepsis, with significantly higher levels found in septic shock than sepsis patients and a clear dose-response relationship with acute kidney injur

    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$HSKA
$VNRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HSKA
$VNRX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$HSKA
$VNRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$HSKA
$VNRX
SEC Filings

See more

$HSKA
$VNRX
Leadership Updates

Live Leadership Updates

See more
  • Volition Issues Business Review 2024

    HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.Continued to strengthen our strategic patent portfolio.Made significant progress a

    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Volition Appoints Timothy I. Still as Chairman

    HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development

    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Volition Appoints Dr. Ethel Rubin as an Independent Director

    HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of organizations – from early-stage operations to large global corporate businesses

    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$HSKA
$VNRX
Financials

Live finance-specific insights

See more
  • VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

    Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.  , Nov. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter of 2024. Volition management will host a conference call tomorrow, November 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Highlights Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 17 countries worldwid

    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update

    Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Nov. 8, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter 2024, in addition to providing a business update. Details of this event can be found below. Event: VolitionRx Limited Third Quarter 2024 Earnings and Business Update Conference Call Date: Friday, November 15, 2024 Time: 8:30 a.m. U.S. Eastern Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll free)Toll/Internati

    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update

    Conference call to take place on Thursday August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Aug. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announced it will host a conference call on Thursday, August 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter 2024, in addition to providing a business update. Details of this event can also be found below. Event: VolitionRx Limited Second Quarter 2024 Earnings and Business Update Conference Call Date: Thursday, August 15, 2024Time: 8:30 a.m. U.S. Eastern Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll free)Toll/Internati

    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$HSKA
$VNRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more